Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:NKTR
Previous Symbol
CUSIP64026810
Phone415-482-5300
Debt
Debt-to-Equity Ratio0.14
Current Ratio13.93
Quick Ratio13.80
Price-To-Earnings
Trailing P/E Ratio-66.65
Forward P/E Ratio10.02
P/E GrowthN/A
Sales & Book Value
Annual Sales$30.71 million
Price / Sales206.60
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.56 per share
Price / Book65.46
Profitability
EPS (Most Recent Fiscal Year)($0.55)
Net Income$-96,690,000.00
Net Margins59.71%
Return on Equity79.66%
Return on Assets54.32%
Miscellaneous
Employees509
Outstanding Shares173,090,000
Market Cap$6.40 billion
OptionableOptionable
Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions
What is Nektar Therapeutics' stock symbol?
Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."
How were Nektar Therapeutics' earnings last quarter?
Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.63) by $0.07. The biopharmaceutical company had revenue of $27.80 million for the quarter, compared to the consensus estimate of $26.08 million. Nektar Therapeutics had a return on equity of 79.66% and a net margin of 59.71%. The firm's revenue for the quarter was down 81.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.37 EPS. View Nektar Therapeutics' Earnings History.
When is Nektar Therapeutics' next earnings date?
What price target have analysts set for NKTR?
10 analysts have issued 12 month price objectives for Nektar Therapeutics' stock. Their predictions range from $47.00 to $125.00. On average, they anticipate Nektar Therapeutics' stock price to reach $86.6667 in the next year. This suggests a possible upside of 134.3% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.
What is the consensus analysts' recommendation for Nektar Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nektar Therapeutics.
What are Wall Street analysts saying about Nektar Therapeutics stock?
Here are some recent quotes from research analysts about Nektar Therapeutics stock:
- 1. According to Zacks Investment Research, "Nektar has a promising pipeline with several pipeline and regulatory updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik, Adynovate and Neulasta under the license agreement with AstraZeneca, Shire and Amgen, respectively. Also, its recent co-development deal with Lilly for NKTR-358 and Bristol-Myers for NKTR-214 is encouraging. The deals provide revenues as well as reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company. Shares of the company have underperformed the industry so far this year." (12/11/2018)
- 2. HC Wainwright analysts commented, "Given the rapid changes in commercially vital TNBC, where peers have surged forward, we incorporated a number of changes to our assumptions, including: (1) after analysis of competitor combination data in TNBC, SCLC and RCC, we have removed TNBC from our model entirely; and (2) additionally, we have reduced our peak adoption estimates in RCC to 15% from 20%, and SCLC to 15% from 25%. 2018, we had eliminated NSCLC from our model." (11/5/2018)
- 3. Mizuho analysts commented, "We highlighted results in our previous note here. Nektar, in collaboration with Bristol Myers, is expected to initiate a phase 3 registrational trial in first- line melanoma in 3Q18. In addition, pivotal studies are also currently being designed and expected to start in 2018 for renal cell carcinoma (RCC) and urothelial cancer (UC)." (8/9/2018)
Has Nektar Therapeutics been receiving favorable news coverage?
Media coverage about NKTR stock has trended somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nektar Therapeutics earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the near term.
Are investors shorting Nektar Therapeutics?
Nektar Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 17,381,864 shares, an increase of 10.0% from the October 31st total of 15,803,369 shares. Based on an average daily trading volume, of 3,354,597 shares, the days-to-cover ratio is currently 5.2 days. Approximately 10.2% of the shares of the stock are short sold. View Nektar Therapeutics' Current Options Chain.
Who are some of Nektar Therapeutics' key competitors?
Some companies that are related to Nektar Therapeutics include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO) and Ionis Pharmaceuticals (IONS).
Who are Nektar Therapeutics' key executives?
Nektar Therapeutics' management team includes the folowing people:
- Mr. Howard W. Robin, CEO, Pres & Director (Age 65)
- Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 46)
- Mr. John Nicholson, Sr. VP & COO (Age 66)
- Dr. Stephen K. Doberstein, Sr. VP of R&D and Chief R&D Officer (Age 59)
- Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 64)
Who are Nektar Therapeutics' major shareholders?
Nektar Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (13.87%), Primecap Management Co. CA (11.64%), Vanguard Group Inc (10.93%), BlackRock Inc. (7.61%), OppenheimerFunds Inc. (6.93%) and Janus Henderson Group PLC (2.63%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.
Which major investors are selling Nektar Therapeutics stock?
NKTR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Primecap Management Co. CA, Carillon Tower Advisers Inc., Janus Henderson Group PLC, Jane Street Group LLC, Mitsubishi UFJ Trust & Banking Corp, Pictet Asset Management Ltd. and Tobam. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.
Which major investors are buying Nektar Therapeutics stock?
NKTR stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Vanguard Group Inc, BlackRock Inc., OppenheimerFunds Inc., BB Biotech AG, Candriam Luxembourg S.C.A., AXA and Bank of New York Mellon Corp. View Insider Buying and Selling for Nektar Therapeutics.
How do I buy shares of Nektar Therapeutics?
Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nektar Therapeutics' stock price today?
One share of NKTR stock can currently be purchased for approximately $36.9850.
How big of a company is Nektar Therapeutics?
Nektar Therapeutics has a market capitalization of $6.40 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe.
What is Nektar Therapeutics' official website?
How can I contact Nektar Therapeutics?
Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]
MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
